Veracyte Highlights Practice-Changing Cancer Test Data at ASCO 2026
SOUTH SAN FRANCISCO, California, 21 May 2026 Veracyte, Inc. announced that major Phase III clinical trial results involving its...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SOUTH SAN FRANCISCO, California, 21 May 2026 Veracyte, Inc. announced that major Phase III clinical trial results involving its...
NASHIK, India, May 21, 2026 Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving...
IRVING, Texas, May 8, 2026 Caris Life Sciences® has submitted an application to the New York State Department of...
SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Irvine, California, March 16, 2026 mdxhealth SA announced new clinical data from the ProMPT study led by the University...
INDIANAPOLIS, Feb. 16, 2026 — Eli Lilly and Company announced positive Phase III results demonstrating that Retevmo® (selpercatinib) delivered...
Boston, MA – December 2025 – The global Clinical Oncology Next-Generation Sequencing (NGS) market is expanding rapidly as cancer...
TORONTO, Sept. 2, 2025 – Geneseeq Technology Inc. announced that its GeneseeqPrime® NGS Tumor Profiling Assay has received 510(k)...
